Monoclonal Antibody Therapy for Covid-19 Positive Patients

Independent Health has been monitoring the encouraging results of Monoclonal Antibody Infusion treatment, which has shown to treat mild to moderate COVID-19 in adults and children who meet specific criteria and are at high risk of severe progression of the illness.

This treatment has been approved under the FDA’s Emergency Use Authorization. There are specific criteria patients must meet in order to receive this therapy.

As part of our commitment to support physicians and the community in the battle against COVID-19, Independent Health is sharing this information to help increase the use of monoclonal antibody treatment and lessen the risk of serious illness or death among those suffering from this illness.

General Overview

What: Monoclonal Antibody Therapy is a treatment for high-risk patients who were recently diagnosed with mild to moderate COVID-19. These high-risk patients have comorbidities which put them at a higher likelihood of progressing to severe disease and/or hospitalization.

Independent Health covers this treatment for patients who present with COVID-19 symptoms and meet the criteria.

Who: Patients who meet the high-risk criteria found at the chart to the right and have been recently diagnosed (within 10 days of symptom onset) with mild to moderate COVID-19.

Why: Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.

When :The drug should be given as soon as possible after a SARS-CoV-2 positive test result and within 10 days of COVID-19 symptom onset.

How: Monoclonal Antibody Therapy is administered via infusion over at least 60 minutes. Patients should be monitored for hypersensitivity reactions for at least 1 hour after completion of the infusion. The diluted solution for infusion should be used immediately after it is prepared. If immediate use is not possible, it can be stored in the refrigerator for up to 24 hours or at room temperature for up to 7 hours, including infusion time.

Where: Patients should be treated in a facility and/or by staff equipped to manage anaphylaxis. Currently hospitals, skilled nursing facilities and home care agencies are eligible providers for administration of this therapy.


Participating facilities

Catholic Health

Erie County Medical Center

Download the ECMC Intake Form

Bertrand Chaffee Hospital

  • Contact Edwin Heidelberger, M.D. for information at 716-592-8140

Catholic Health

DeGraff Memorial Medical Park

  • Phone: 716-690-2266
  • Complete Referral Packet in full, and fax paperwork to 716-690-2263 between Monday through Thursday from 7:00 a.m. to 3:30 p.m.
  • The office will directly contact the patients who qualify to schedule the appointment.
  • Note: Referrals for this treatment are restricted to providers with admitting or referring privileges at Kaleida who are able to independently order the medication. There will be no onsite provider available to place the order.

Download the Intake Forms

Niagara Falls Memorial Medical Center

  • Rajinder Bajwa, M.D.
  • Hours: Monday through Friday from 8:00 a.m. to 12:00 p.m. (Extended hours available on demand)
  • Call Dr. Bajwa regardless of time/date: Weekends through ED
  • The goal of the office is to schedule infusion within 24 hours of receiving initial information.
  • E-mail contacts: and
  • Referral steps:
    • Contact Dr. Bajwa’s assistant, Lisa Roundtree by phone at 716-278-4820 or by fax at 716-278-4825, to review patient information. She will arrange phone consult with either Dr. Bajwa or Dr. Salehi.
    • Dr. Bajwa’s office
    • will then contact Central Scheduling to make the infusion appointment for the patient.

Note: there is no intake form; please contact the individuals named above.

United Memorial Medical Center

  • Contact the center's Emergency Department at 585-343-6030

High Risk Patient Criteria

Patients with one or more of the following:

  • BMI ≥ 35
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease
  • Currently receiving immunosuppressive treatment
  • 65 years old or older

Patients 55 years old or older and one or more of the following:

  • Cardiovascular disease
  • Hypertension
  • COPD or other chronic respiratory disease

Patients 12 to 17 years old and one or more of the following:

  • BMI ≥ 85th percentile for their age and gender
  • Sickle cell disease
  • Congenital or acquired heart disease
  • Neurodevelopmental disorders (e.g., cerebral palsy)
  • A medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])
  • Asthma, reactive airway or other chronic respiratory disease that requires daily treatment

(Source: American Medical Association, 2020)